Zoe Goddard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zoe Goddard has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Mark Searcey
University of East Anglia
8 shared publications - Andrew Michael Beekman
University of East Anglia
6 shared publications Marco M. D. Cominetti
School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, Norfolk, NR47TJ, UK
3 shared publications- Maria Anne O'Connell
University of East Anglia
3 shared publications - David A. Russell
School of Chemistry, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK
2 shared publications - Marco Cominetti
University of East Anglia
2 shared publications
Latest Publications
- Open Access
- 2 December 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Structure-based peptide design identifies inhibitors of the dyskerin/dyskerin interaction in H/ACA ribonucleoproteins targeting brain tumour cell lines
H/ACA ribonucleoparticles (RNPs) play key regulatory roles in ribosome biogenesis, splicing, and telomerase maintenance and their activities are enhanced in cancer cells. The central component of H/ACA RNPs is the enzyme dyskerin (DKC1). DKC1 has high expression in multiple tumour types, and contributes to cancer hallmarks, tumour growth and cellular immortalization. DKC1 mutations also cause dyskeratosis congenita, a premature-ageing syndrome characterised by hindered ribosome biogenesis and shortened telomeres. We leveraged genetic information to devise a strategy to generate dyskerin inhibitors. Mapping of DKC1 mutations on the cryo-EM structures of H/ACA RNP showed they alter the dyskerin/dyskerin protein-protein interaction in this complex. Based on this, we designed and synthesised peptides that inhibit dyskerin dimerization and developed in vitro protein assays demonstrating protein engagement and interaction inhibition. Lead peptides were tested in brain tumour cells (medulloblastoma and glioblastoma) and caused alterations in cell growth, viability, apoptosis, protein synthesis and snoRNA and telomerase RNA (hTERT) levels. These results suggest for the first time that inhibition of the protein interactions within the H/ACA RNP offers a new target for cancer treatment.
- 2 December 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessStructure-based peptide design identifies inhibitors of the dyskerin/dyskerin interaction in H/ACA ribonucleoproteins targeting brain tumour cell lines
H/ACA ribonucleoparticles (RNPs) play key regulatory roles in ribosome biogenesis, splicing, and telomerase maintenance and their activities are enhanced in cancer cells. The central component of H/ACA RNPs is the enzyme dyskerin (DKC1). DKC1 has high expression in multiple tumour types, and contributes to cancer hallmarks, tumour growth and cellular immortalization. DKC1 mutations also cause dyskeratosis congenita, a premature-ageing syndrome characterised by hindered ribosome biogenesis and shortened telomeres. We leveraged genetic information to devise a strategy to generate dyskerin inhibitors. Mapping of DKC1 mutations on the cryo-EM structures of H/ACA RNP showed they alter the dyskerin/dyskerin protein-protein interaction in this complex. Based on this, we designed and synthesised peptides that inhibit dyskerin dimerization and developed in vitro protein assays demonstrating protein engagement and interaction inhibition. Lead peptides were tested in brain tumour cells (medulloblastoma and glioblastoma) and caused alterations in cell growth, viability, apoptosis, protein synthesis and snoRNA and telomerase RNA (hTERT) levels. These results suggest for the first time that inhibition of the protein interactions within the H/ACA RNP offers a new target for cancer treatment.
- Open Access
- 9 July 2024
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 60 (63) , 8228-8231
Light-activated azobenzene peptide inhibitor of the PD-1/PD-L1 interaction
A photoswitch peptide that binds to PD-1/PD-L1 only in the cis conformation, allowing for external control of the immune checkpoint interaction.
- 9 July 2024
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 60 (63) , 8228-8231
Open AccessLight-activated azobenzene peptide inhibitor of the PD-1/PD-L1 interaction
A photoswitch peptide that binds to PD-1/PD-L1 only in the cis conformation, allowing for external control of the immune checkpoint interaction.
- Open Access
- 18 June 2024
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 22 (27) , 5603-5607
Borylation via iridium catalysed C–H activation: a new concise route to duocarmycin derivatives
A concise synthesis of an alkylation subunit of the duocarmycins is achieved via a C–H-activation approach. The ethyl ester analogue of duocarmycin SA can be made in eleven linear steps from a commercially available precursor.
- 18 June 2024
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 22 (27) , 5603-5607
Open AccessBorylation via iridium catalysed C–H activation: a new concise route to duocarmycin derivatives
A concise synthesis of an alkylation subunit of the duocarmycins is achieved via a C–H-activation approach. The ethyl ester analogue of duocarmycin SA can be made in eleven linear steps from a commercially available precursor.
- Open Access
- 24 April 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Borylation via Iridium catalysed C-H activation: a new concise route to duocarmycin derivatives
The synthesis of the ethyl ester analogue of the ultapotent antitumour antibiotic seco-duocarmycin SA has been achieved in eleven linear steps from commercially available starting materials. The DSA alkylation subunit can be made in ten linear steps from the same precursor. The route involves CH activation at the equivalent of the C7 position on indole leading to a borylated intermediate 9 that is stable enough for coupling reactions but can be easily converted to the free hydroxyl analogue.
- 24 April 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessBorylation via Iridium catalysed C-H activation: a new concise route to duocarmycin derivatives
The synthesis of the ethyl ester analogue of the ultapotent antitumour antibiotic seco-duocarmycin SA has been achieved in eleven linear steps from commercially available starting materials. The DSA alkylation subunit can be made in ten linear steps from the same precursor. The route involves CH activation at the equivalent of the C7 position on indole leading to a borylated intermediate 9 that is stable enough for coupling reactions but can be easily converted to the free hydroxyl analogue.
- Open Access
- 4 March 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Light-Activated Azobenzene Peptide Inhibitor of the PD-1/PD-L1 Interaction
Inhibiting the protein-protein interaction between programmed cell death 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1) has become a focal point in immunotherapy for cancer treatments. Limitations of antibody treatments remain prevalent leaving an urgent need for alternative inhibitors of PD-1/PD-L1. Utilizing the photo-switching ability of the well studied azobenzenes, we developed a photo-controlled PD-1/PD-L1 peptide inhibitor. The azobenzene peptide selectively inhibits the PD-1/PD-L1 interaction when in the cis isomer, while showing no appreciable inhibition in the trans isomer. The light-activated inhibitor demonstrated improved activity compared to the canonical peptide it was derived from in a luminescent cell-based PD-1/PD-L1 blockade assay. The light-activated peptide demonstrates the applicatbilty of photoisomerization for mimicking β-hairpin motifs in PD-1/PD-L1 inhibition.
- 4 March 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessLight-Activated Azobenzene Peptide Inhibitor of the PD-1/PD-L1 Interaction
Inhibiting the protein-protein interaction between programmed cell death 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1) has become a focal point in immunotherapy for cancer treatments. Limitations of antibody treatments remain prevalent leaving an urgent need for alternative inhibitors of PD-1/PD-L1. Utilizing the photo-switching ability of the well studied azobenzenes, we developed a photo-controlled PD-1/PD-L1 peptide inhibitor. The azobenzene peptide selectively inhibits the PD-1/PD-L1 interaction when in the cis isomer, while showing no appreciable inhibition in the trans isomer. The light-activated inhibitor demonstrated improved activity compared to the canonical peptide it was derived from in a luminescent cell-based PD-1/PD-L1 blockade assay. The light-activated peptide demonstrates the applicatbilty of photoisomerization for mimicking β-hairpin motifs in PD-1/PD-L1 inhibition.
- Open Access
- 19 November 2020
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 12 (2) , 288-292
Peptide directed phthalocyanine–gold nanoparticles for selective photodynamic therapy of EGFR overexpressing cancers
Gold nanoparticles, covalently functionalised with the photosensitiser C11Pc and PEG, were actively targeted towards epidermal growth factor receptor overexpressing cancers using the peptide FITC-βAAEYLRK, with selective phototoxicty observed.
- 19 November 2020
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 12 (2) , 288-292
Open AccessPeptide directed phthalocyanine–gold nanoparticles for selective photodynamic therapy of EGFR overexpressing cancers
Gold nanoparticles, covalently functionalised with the photosensitiser C11Pc and PEG, were actively targeted towards epidermal growth factor receptor overexpressing cancers using the peptide FITC-βAAEYLRK, with selective phototoxicty observed.
- Open Access
- 22 October 2020
- Published by Royal Society of Chemistry (RSC) in Chemical Society Reviews
- Vol. 49 (23) , 8774-8789
Active targeting of gold nanoparticles as cancer therapeutics
Gold nanoparticles are excellent delivery systems, but how can we get them where we want them to go?
- 22 October 2020
- Published by Royal Society of Chemistry (RSC) in Chemical Society Reviews
- Vol. 49 (23) , 8774-8789
Open AccessActive targeting of gold nanoparticles as cancer therapeutics
Gold nanoparticles are excellent delivery systems, but how can we get them where we want them to go?